Functional analysis of Caspase-4 in non-small cell lung cancer cells
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA985671 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| SRR24974776_1.fastq.gz | Fastqsanger.gz | |||
| SRR24974776_2.fastq.gz | Fastqsanger.gz | |||
| SRR24974777_1.fastq.gz | Fastqsanger.gz | |||
| SRR24974777_2.fastq.gz | Fastqsanger.gz | |||
| SRR24974778_1.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 18 |
Similar Datasets
Project description:To clarify the role of Caspase-4 in non-small cell lung cancer cells, Caspase-4 overexpressing and knockout cells in NCI-H292 cells were established and each was analyzed by RNAseq.
2023-06-21 | GSE235296 | GEO
Project description:Purpose: finding differential transcripts usage in environmentally harzardous chemical, mercury chloride (HgCl2) in human non-small cell lung carcinoma cells Methods: transcriptome analysis by the RNA-seq via mRNA pull-down Results: We found that HgCl2 increases cellular toxicity by the increasing of apoptosis via caspase-3 independent pathway in H12999 cells. Also, over thounds of altered gene expression pattern were detected from the RNA-seq analysis. Conclusions: mercury chloride (HgCl2) increases cytotoxic effects and apoptosis in H1299 cells through the caspase-3 independent pathway and changes the context of trascript
2021-03-10 | GSE163937 | GEO
Project description:Mimicry of neuronal features is emerging as malignant regulator of cancer growth and metastasis. Neuroendocrine (NE) cancers including small cell lung cancers (SCLC) have been shown to share expression profiles marking various stages of neuronal differentiation. Yet, how these state changes are caused and malignant consequences thereof have remained unexplored.Here, we devise a novel mouse model of SCLC recapitulating low expression of caspase 8 as seen in humans and uncover that this allows for epigenetic reprogramming towards a more aggressive and metastasising stem-cell like neuronal state, resembling neuronal intermediate progenitor cells (nIPCs). Notably, transcriptional signatures of this cellular state are enriched in relapsed and metastatic human SCLC. Mechanistically, caspase 8 loss within the pre-tumoral niche promoted immunosuppression and metastasis via induction of immunogenic cell death. Inactivation of the necroptosis executioner Mixed lineage kinase domain-like protein (MLKL) neutralised caspase 8 loss-induced immunosuppression, metastasis and diminished the stem-cell like state providing genetic evidence for a role of necroptosis in promoting these effects. Collectively our data uncover an unexpected role for low expression of caspase 8 in directing neuronal-like reprogramming towards an immunosuppressive and highly metastatic state in SCLC.
2025-11-05 | GSE274809 | GEO
Project description:Mimicry of neuronal features is emerging as malignant regulator of cancer growth and metastasis. Neuroendocrine (NE) cancers including small cell lung cancers (SCLC) have been shown to share expression profiles marking various stages of neuronal differentiation. Yet, how these state changes are caused and malignant consequences thereof have remained unexplored.Here, we devise a novel mouse model of SCLC recapitulating low expression of caspase 8 as seen in humans and uncover that this allows for epigenetic reprogramming towards a more aggressive and metastasising stem-cell like neuronal state, resembling neuronal intermediate progenitor cells (nIPCs). Notably, transcriptional signatures of this cellular state are enriched in relapsed and metastatic human SCLC. Mechanistically, caspase 8 loss within the pre-tumoral niche promoted immunosuppression and metastasis via induction of immunogenic cell death. Inactivation of the necroptosis executioner Mixed lineage kinase domain-like protein (MLKL) neutralised caspase 8 loss-induced immunosuppression, metastasis and diminished the stem-cell like state providing genetic evidence for a role of necroptosis in promoting these effects. Collectively our data uncover an unexpected role for low expression of caspase 8 in directing neuronal-like reprogramming towards an immunosuppressive and highly metastatic state in SCLC.
2025-11-05 | GSE274232 | GEO
Project description:Non-small Cell Lung Cancer Brain Metastasis Atlas
| PRJNA926591 | ENA
Project description:RNA profilling of non-small cell lung cancer
| PRJEB27606 | ENA
Project description:Caspases are a highly conserved family of cysteine-aspartyl proteases known for their essential roles in regulating apoptosis, inflammation, cell differentiation and proliferation. Complementary to genetic approaches, small molecule inhibitors have emerged as useful tools for modulating caspase activity. Achieving high selectivity remains a central challenge for caspase-directed inhibitor development efforts, due to the high sequence and structure homology of all twelve human caspases. Here, using a chemoproteomic approach, we first identify a highly reactive non-catalytic cysteine that is unique to caspase-2. By combining both gel-based activity-based protein profiling (ABPP) and a TEV activation assay, we then identify covalent lead compounds that react preferentially with this cysteine and afford a complete blockade of caspase-2 activity. Inhibitory activity is restricted to the zymogen or precursor form of monomeric caspase-2, with compound treatment blocking intramolecular caspase interactions. Focused medicinal chemistry combined with chemoproteomic target engagement analysis in lysates and in cells yielded both caspase-2 selective and promiscuous caspase inhibitors, together with structurally matched inactive control compounds. Application of this focused set of tool compounds to stratify caspase contributions to activation of intrinsic apoptosis indicate likely compensatory caspase-9 activity driving etoposide-mediated cell death in the context of caspase-2 inactivation. More broadly, our study highlights the utility of targeting non-conserved and non-catalytic cysteine residues for achieving improved selectivity profiles for highly homologous families of enzymes.
2025-01-14 | PXD042362 | Pride
Project description:Caspases are a highly conserved family of cysteine-aspartyl proteases known for their essential roles in regulating apoptosis, inflammation, cell differentiation and proliferation. Complementary to genetic approaches, small molecule inhibitors have emerged as useful tools for modulating caspase activity. Achieving high selectivity remains a central challenge for caspase-directed inhibitor development efforts, due to the high sequence and structure homology of all twelve human caspases. Here, using a chemoproteomic approach, we first identify a highly reactive non-catalytic cysteine that is unique to caspase-2. By combining both gel-based activity-based protein profiling (ABPP) and a TEV activation assay, we then identify covalent lead compounds that react preferentially with this cysteine and afford a complete blockade of caspase-2 activity. Inhibitory activity is restricted to the zymogen or precursor form of monomeric caspase-2, with compound treatment blocking intramolecular caspase interactions. Focused medicinal chemistry combined with chemoproteomic target engagement analysis in lysates and in cells yielded both caspase-2 selective and promiscuous caspase inhibitors, together with structurally matched inactive control compounds. Application of this focused set of tool compounds to stratify caspase contributions to activation of intrinsic apoptosis indicate likely compensatory caspase-9 activity driving etoposide-mediated cell death in the context of caspase-2 inactivation. More broadly, our study highlights the utility of targeting non-conserved and non-catalytic cysteine residues for achieving improved selectivity profiles for highly homologous families of enzymes.
2025-01-14 | PXD046269 | Pride
Project description:Caspases are a highly conserved family of cysteine-aspartyl proteases known for their essential roles in regulating apoptosis, inflammation, cell differentiation and proliferation. Complementary to genetic approaches, small molecule inhibitors have emerged as useful tools for modulating caspase activity. Achieving high selectivity remains a central challenge for caspase-directed inhibitor development efforts, due to the high sequence and structure homology of all twelve human caspases. Here, using a chemoproteomic approach, we first identify a highly reactive non-catalytic cysteine that is unique to caspase-2. By combining both gel-based activity-based protein profiling (ABPP) and a TEV activation assay, we then identify covalent lead compounds that react preferentially with this cysteine and afford a complete blockade of caspase-2 activity. Inhibitory activity is restricted to the zymogen or precursor form of monomeric caspase-2, with compound treatment blocking intramolecular caspase interactions. Focused medicinal chemistry combined with chemoproteomic target engagement analysis in lysates and in cells yielded both caspase-2 selective and promiscuous caspase inhibitors, together with structurally matched inactive control compounds. Application of this focused set of tool compounds to stratify caspase contributions to activation of intrinsic apoptosis indicate likely compensatory caspase-9 activity driving etoposide-mediated cell death in the context of caspase-2 inactivation. More broadly, our study highlights the utility of targeting non-conserved and non-catalytic cysteine residues for achieving improved selectivity profiles for highly homologous families of enzymes.
2025-01-14 | PXD051381 | Pride
Project description:Identification of Key Gene and Functional Pathways in Radioresistance of non-small cell lung cancer
| PRJNA809408 | ENA